Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is engaged in establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company is currently focused on bladder cancer, the most expensive cancer to treat due to a high 50% recurrence rate that leaves approximately 600,000 U.S. patients living in fear that their cancer will return. Imagin Medical’s i/Blue(TM) Imaging System has the ability to overcome limitations of today’s white and blue light cystoscopy procedures. The innovative technology enables surgeons to see real-time white and blue light images on the screen simultaneously during a procedure. This technology provides much promise in the visualization and removal of bladder cancer, the sixth most prevalent type of cancer in the United States. A recent article discussing this reads, “Led by a management team with significant experience in the market, both in medical device implementation and MIS, Imagin Medical is confident that its technology has the potential to revolutionize the current standard of care for bladder cancer patients, positioning the company as a leading provider of effective solutions in the vast market of bladder cancer visualization.”
To view the full article, visit https://ibn.fm/sGxy5
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork